BioCryst Pharmaceuticals reported 6.84 in PE Price to Earnings for its fiscal quarter ending in June of 2026.





Pe Change Date
Alnylam Pharmaceuticals 13.17 62.47 Sep/2026
BioCryst Pharmaceuticals 6.84 0.78 Jun/2026
Chugai Pharma 21.73 2.58 Sep/2026
Daiichi Sankyo 18.6 1.54 Sep/2026
Gilead Sciences 17.68 4.18 Sep/2026
GlaxoSmithKline 9.72 0.9 Sep/2026
Glaxosmithkline 15.17 0.08 Sep/2026
Incyte 54.54 40.08 Sep/2026
Ionis Pharmaceuticals 396.15 79.28 Sep/2022
Neurocrine Biosciences 83.17 61.07 Sep/2026
Novavax 2.01 1.07 Dec/2025
PTC Therapeutics 8.76 0 Jun/2026
Regeneron Pharmaceuticals 15.46 9.68 Jun/2026
Roche Holding 16.48 0.39 Jun/2026
Sarepta Therapeutics 32.09 22.66 Sep/2026
Vertex Pharmaceuticals 29.35 1.3 Sep/2026